Next Article in Journal
Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment
Next Article in Special Issue
Androgen Receptor Could Be a Potential Therapeutic Target in Patients with Advanced Hepatocellular Carcinoma
Previous Article in Journal
ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology
Previous Article in Special Issue
The Androgen Receptor and VEGF: Mechanisms of Androgen-Regulated Angiogenesis in Prostate Cancer
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessReview
Cancers 2017, 9(4), 34;

AR Signaling and the PI3K Pathway in Prostate Cancer

Kinghorn Cancer Centre, St Vincent’s Hospital, 370 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia
Garvan Institute of Medical Research, St Vincent’s Clinical School, University of New South Wales, Sydney, 384 Victoria St, Darlinghurst, Sydney, NSW 2010, Australia
AstraZeneca UK, Clinical Discovery Unit, Early Clinical Development Innovative Medicines, da Vinci Building, Melbourn Science Park, Melbourn, Hertfordshire SG8 6HB, UK
Addenbrookes Hospital, Cambridge University Hospitals NHS Foundation Trust Cambridge Biomedical Campus, Hills Rd, Cambridge CB2 0QQ, UK
Princess Margaret Cancer Centre, University Health Network, University of Toronto, University Avenue, Toronto, ON M5G 2M9, Canada
Author to whom correspondence should be addressed.
Academic Editor: Emmanuel S. Antonarakis
Received: 27 February 2017 / Revised: 4 April 2017 / Accepted: 11 April 2017 / Published: 15 April 2017
(This article belongs to the Special Issue AR Signaling in Human Malignancies: Prostate Cancer and Beyond)
Full-Text   |   PDF [399 KB, uploaded 19 April 2017]   |  


Prostate cancer is a leading cause of cancer-related death in men worldwide. Aberrant signaling in the androgen pathway is critical in the development and progression of prostate cancer. Despite ongoing reliance on androgen receptor (AR) signaling in castrate resistant disease, in addition to the development of potent androgen targeting drugs, patients invariably develop treatment resistance. Interactions between the AR and PI3K pathways may be a mechanism of treatment resistance and inhibitors of this pathway have been developed with variable success. Herein we outline the role of the PI3K pathway in prostate cancer and, in particular, its association with androgen receptor signaling in the pathogenesis and evolution of prostate cancer, as well as a review of the clinical utility of PI3K targeting. View Full-Text
Keywords: PI3K; prostate cancer; AR signaling; castrate resistant prostate cancer PI3K; prostate cancer; AR signaling; castrate resistant prostate cancer

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Crumbaker, M.; Khoja, L.; Joshua, A.M. AR Signaling and the PI3K Pathway in Prostate Cancer. Cancers 2017, 9, 34.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top